Short answer · Medically reviewed summary · Last updated: 2026-04-06
The management of Aniridia is primarily focused on the preservation of visual function and the mitigation of secondary ocular complications through a combination of lifelong surveillance and targeted symptom management. First-Line Treatments and Medical Management Because Aniridia is a pan-ocular condition, treatment is highly personalized based on the specific anatomical deficits, such as iris hypoplasia, foveal hypoplasia, and corneal epithelial stem cell deficiency. Initial care centers on aggressive lubrication using preservative-free artificial tears (e.g., carboxymethylcellulose or hyaluronic acid) to manage ocular surface disease.
5 people with Aniridia have shared their first-person experience on this question at DiseaseMaps.
The management of Aniridia is primarily focused on the preservation of visual function and the mitigation of secondary ocular complications through a combination of lifelong surveillance and targeted symptom management.
Because Aniridia is a pan-ocular condition, treatment is highly personalized based on the specific anatomical deficits, such as iris hypoplasia, foveal hypoplasia, and corneal epithelial stem cell deficiency. Initial care centers on aggressive lubrication using preservative-free artificial tears (e.g., carboxymethylcellulose or hyaluronic acid) to manage ocular surface disease. Patients are often prescribed tinted contact lenses or specialized spectacles to reduce photophobia caused by the lack of an iris.
When glaucoma develops—a common complication in Aniridia—management may involve topical anti-glaucoma medications like latanoprost or dorzolamide (Trusopt). If medical therapy fails to control intraocular pressure, surgical intervention such as goniotomy or the implantation of a glaucoma drainage device may be required. For patients with limbal stem cell deficiency, limbal stem cell transplantation (LSCT) remains a significant surgical consideration to restore corneal clarity, though outcomes vary based on individual ocular health.
Effective management of Aniridia requires a multidisciplinary care team, typically including an ophthalmologist specializing in anterior segment disease, a glaucoma specialist, a clinical geneticist, and an occupational therapist or vision rehabilitation specialist. Because Aniridia is often associated with systemic conditions, such as WAGR syndrome, regular monitoring of renal function and developmental milestones is essential for pediatric patients.
Current clinical research is exploring gene-specific therapies and advanced regenerative medicine techniques to address the underlying PAX6 gene mutation. While no curative treatment currently exists, the medical community is actively investigating novel approaches to stabilize the ocular surface and improve visual outcomes in those living with this rare condition.
Disclaimer: This information is for educational purposes only and does not constitute medical advice. All treatment plans for Aniridia must be tailored to the individual patient by their dedicated medical team. Please consult your physician regarding your specific clinical needs.